1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Venus Remedies Limited

Venus Remedies Limited

VENUSREM.BO
Venus Remedies LimitedIN flagBombay Stock Exchange
1,664.65
INR
-73.35
- -
22.36BMarket Cap

Total Valuation

Venus Remedies Limited carries a market capitalization of 22.36B, placing it among publicly traded companies globally. Its enterprise value stands at 10.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap22.36B
Enterprise Value10.12B

Share Statistics

Venus Remedies Limited currently has 13.37M shares outstanding.

Shares Outstanding13.37M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Venus Remedies Limited trades at a trailing price-to-earnings ratio of 10.74. The price-to-sales ratio is 1.44, and the price-to-book ratio stands at 82.54.

PE Ratio10.74
PS Ratio1.44
PB Ratio82.54
P/TBV Ratio1.94
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Venus Remedies Limited trades at an EV/EBITDA multiple of 8.70 and an EV/FCF ratio of 33,021.96. The EV/Sales ratio of 1.32 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.70 provides insight into valuation relative to core operating earnings.

EV / Sales1.32
EV / EBITDA8.70
EV / EBIT8.70
EV / FCF33,021.96

Financial Position

Venus Remedies Limited maintains a current ratio of 2.44, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.87, indicating elevated leverage, while an interest coverage ratio of 2,908.25 demonstrates limited ability to service its debt obligations.

Current Ratio2.44
Quick Ratio0.64
Debt / Equity1.87
Debt / EBITDA0.11
Interest Coverage2,908.25

Financial Efficiency

Venus Remedies Limited posts a return on equity of 84.96 and a return on invested capital of 14.39.

Return on Equity (ROE)84.96
Return on Assets (ROA)13.10
Return on Invested Capital (ROIC)14.39
Return on Capital Employed (ROCE)80.30
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.37

Taxes

Over the trailing twelve months, Venus Remedies Limited has paid 313.70M in income taxes, reflecting an effective tax rate of 23.38.

Income Tax313.70M
Effective Tax Rate23.38

Stock Price Statistics

Venus Remedies Limited's stock has gained approximately 285.38025% over the past 52 weeks. The 50-day moving average sits at 1,371.33, while the 200-day moving average is 871.29.

Beta (5Y)N/A
52-Week Price Change285.38025%
50-Day Moving Average1,371.33
200-Day Moving Average871.29
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Venus Remedies Limited generated 7.64B in revenue and converted that into 1.03B in net income, yielding earnings per share of 76.91. EBITDA reached 1.16B, while operating income came in at 1.16B.

Revenue7.64B
Gross Profit3.77B
Operating Income1.16B
Pretax Income1.34B
Net Income1.03B
EBITDA1.16B
EBIT1.16B
Earnings Per Share (EPS)76.91

Balance Sheet

Venus Remedies Limited holds 1.04B in cash and equivalents against 124.10M in total debt, resulting in a net debt position of -251.20M. Total book value stands at 133.70M, with working capital of 2.33B providing operational flexibility.

Cash & Cash Equivalents1.04B
Total Debt124.10M
Net Debt-251.20M
Equity (Book Value)133.70M
Book Value Per Share10.00
Working Capital2.33B

Margins

Venus Remedies Limited operates with a gross margin of 49.33, reflecting its pricing power and cost economics. The operating margin of 15.22 and net profit margin of 13.45 provide insight into operational efficiency.

Gross Margin49.33
Operating Margin15.22
Pretax Margin17.55
Profit Margin13.45
EBITDA Margin15.22

Scores

Venus Remedies Limited posts an Altman Z-Score of 5.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.37